Clinical Conductor Adds CTMS Features to Facilitate Dynamic Research
The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.
The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.
This quarter, the development team has added unique features including:
· Budget snapshots for better financial management and negotiations with sponsors
· The ability for organizations to create multiple charge masters
· Protocol versioning – where organizations can create new versions of a protocol and more easily handle amendments that occur
All of these features help solve an existing problem in research where technology can sometimes be lacking: flexibility. Since research is continuously changing, researchers and managers need technology capable of providing the granular data they need to remain profitable and produce high quality clinical research.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
